JP2008529536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529536A5 JP2008529536A5 JP2007555366A JP2007555366A JP2008529536A5 JP 2008529536 A5 JP2008529536 A5 JP 2008529536A5 JP 2007555366 A JP2007555366 A JP 2007555366A JP 2007555366 A JP2007555366 A JP 2007555366A JP 2008529536 A5 JP2008529536 A5 JP 2008529536A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- complement factor
- cfh
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010053085 Complement Factor H Proteins 0.000 claims 54
- 102100035432 Complement factor H Human genes 0.000 claims 49
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 206010064930 age-related macular degeneration Diseases 0.000 claims 26
- 208000002780 macular degeneration Diseases 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 238000000034 method Methods 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 5
- 108010078015 Complement C3b Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102000054766 genetic haplotypes Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 102000016550 Complement Factor H Human genes 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 101150030967 CFH gene Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 102220005747 rs1061170 Human genes 0.000 claims 1
- 102200031812 rs1065489 Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65307805P | 2005-02-14 | 2005-02-14 | |
| US71550305P | 2005-09-09 | 2005-09-09 | |
| US71786105P | 2005-09-16 | 2005-09-16 | |
| US73569705P | 2005-11-09 | 2005-11-09 | |
| PCT/US2006/005313 WO2006088950A2 (en) | 2005-02-14 | 2006-02-14 | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012049810A Division JP5100901B2 (ja) | 2005-02-14 | 2012-03-06 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008529536A JP2008529536A (ja) | 2008-08-07 |
| JP2008529536A5 true JP2008529536A5 (2) | 2009-05-14 |
Family
ID=36917017
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555366A Withdrawn JP2008529536A (ja) | 2005-02-14 | 2006-02-14 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
| JP2012049810A Expired - Fee Related JP5100901B2 (ja) | 2005-02-14 | 2012-03-06 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
| JP2012180904A Withdrawn JP2012254089A (ja) | 2005-02-14 | 2012-08-17 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
| JP2014123102A Pending JP2014204729A (ja) | 2005-02-14 | 2014-06-16 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012049810A Expired - Fee Related JP5100901B2 (ja) | 2005-02-14 | 2012-03-06 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
| JP2012180904A Withdrawn JP2012254089A (ja) | 2005-02-14 | 2012-08-17 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
| JP2014123102A Pending JP2014204729A (ja) | 2005-02-14 | 2014-06-16 | 加齢性黄斑変性を処置および診断するための方法および試薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US7745389B2 (2) |
| EP (5) | EP2377951A1 (2) |
| JP (4) | JP2008529536A (2) |
| KR (2) | KR20070112801A (2) |
| CN (1) | CN103920142A (2) |
| AT (1) | ATE526421T1 (2) |
| AU (1) | AU2006214320C1 (2) |
| CA (1) | CA2597411C (2) |
| IL (2) | IL185219A (2) |
| MX (1) | MX2007009565A (2) |
| NZ (2) | NZ595305A (2) |
| WO (1) | WO2006088950A2 (2) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506629A (pt) * | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| JP2008520242A (ja) * | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| US8088587B2 (en) | 2005-03-04 | 2012-01-03 | Vanderbilt University | Genetic variants increase the risk of age-related macular degeneration |
| US20070037183A1 (en) * | 2005-03-07 | 2007-02-15 | Trustees Of Boston University | Diagnostic and therapeutic target for macular degeneration |
| WO2006128006A1 (en) * | 2005-05-26 | 2006-11-30 | The Regents Of The University Of Colorado | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| EP1937706A4 (en) * | 2005-09-09 | 2008-10-22 | Univ Iowa Res Found | ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| SG10201804008UA (en) * | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| KR20080087814A (ko) * | 2005-12-22 | 2008-10-01 | 알콘 리서치, 리미티드 | 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제 |
| US20080146501A1 (en) * | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| WO2007120975A2 (en) | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
| US7759304B2 (en) * | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| EP2479284B1 (en) | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| ES2391788T3 (es) * | 2006-07-26 | 2012-11-29 | Yale University, Inc. | Diagnóstico y tratamiento de degeneración macular relacionada con la edad |
| EP2054728A2 (en) * | 2006-08-23 | 2009-05-06 | University of Iowa Research Foundation | Biomarkers associated with age-related macular degeneration |
| TW201716437A (zh) | 2006-11-02 | 2017-05-16 | 建南德克公司 | 人類化之抗-因子ｄ抗體及其用途 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| WO2008103299A2 (en) | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
| CN101668773B (zh) | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
| WO2008110828A1 (en) * | 2007-03-14 | 2008-09-18 | Dsm Ip Assets B.V. | Method for prevention of age-related macular degeneration (amd) |
| WO2008110283A2 (en) * | 2007-03-14 | 2008-09-18 | Dsm Ip Assets B.V. | Method for prevention of age-related macular degeneration (amd) |
| CA2680833A1 (en) * | 2007-04-30 | 2008-11-13 | Alcon Research, Ltd. | Treatment of age-related macular degeneration using inhibitors of complement factor d |
| EP2158330A2 (en) * | 2007-05-11 | 2010-03-03 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
| WO2009029587A2 (en) * | 2007-08-24 | 2009-03-05 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating macular degeneration |
| WO2009059321A2 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| AU2009251499B2 (en) * | 2008-04-18 | 2015-07-16 | The General Hospital Corporation | Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk |
| US20110294682A1 (en) * | 2008-04-28 | 2011-12-01 | The General Hospital Corporation | Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| DE102008049136B4 (de) * | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| US20100145223A1 (en) * | 2008-11-26 | 2010-06-10 | Duke University | Peripheral Reticular Pigmentary Change and Age-Related Macular Degeneration |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| GB0911717D0 (en) * | 2009-07-06 | 2009-08-19 | Ucl Business Plc | Method |
| CA2781595C (en) | 2009-07-10 | 2016-07-05 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating macular degeneration |
| AU2010273254A1 (en) * | 2009-07-16 | 2012-02-02 | Glaxo Wellcome Manufacturing Pte Ltd | Treatment method |
| AT516600B1 (de) * | 2009-07-23 | 2016-07-15 | Baxter Int | Herstellung von faktor h (fh) und fh-derivaten aus plasma |
| US8236570B2 (en) * | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| FR2952539B1 (fr) * | 2009-11-16 | 2012-01-13 | Lab Francais Du Fractionnement | Preparation d'un concentre de facteur h |
| GB0922659D0 (en) | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
| DK2569446T3 (en) * | 2010-05-12 | 2018-10-29 | Steven E Schutzer | DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| US20120202708A1 (en) * | 2010-10-14 | 2012-08-09 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| BR112013010769A2 (pt) * | 2010-11-01 | 2019-09-24 | Genentech Inc | predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico |
| US9598733B2 (en) | 2011-02-17 | 2017-03-21 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing IgA nephropathy |
| CN103874526A (zh) * | 2011-04-29 | 2014-06-18 | 犹他大学研究基金会 | 预测补体介导的疾病的发展的方法 |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| US20140004105A1 (en) * | 2012-06-29 | 2014-01-02 | Sequenom, Inc. | Age-related macular degeneration diagnostics |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| EP2895624B1 (en) * | 2012-09-14 | 2022-06-01 | University Of Utah Research Foundation | Methods of predicting the development of amd based on chromosome 1 and chromosome 10 |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| AU2014236778B2 (en) | 2013-03-14 | 2019-01-03 | Baxalta GmbH | Factor H for transplantation |
| WO2014151923A1 (en) | 2013-03-14 | 2014-09-25 | Baxter International Inc. | Factor h for treatment of rheumatoid arthritis |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| US10202647B2 (en) | 2013-04-12 | 2019-02-12 | The Trustees Of Columbia University In The City Of New York | Mutations in DSTYK cause dominant urinary tract malformations |
| US10183988B2 (en) | 2013-06-07 | 2019-01-22 | Duke University | Anti-Complement factor H antibodies |
| SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
| US9977036B2 (en) | 2013-08-15 | 2018-05-22 | Steven E. Schutzer | Diagnostic markers for multiple sclerosis |
| CA2920293A1 (en) | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
| US9953133B2 (en) | 2015-06-03 | 2018-04-24 | General Electric Company | Biological data annotation and visualization |
| US9607375B2 (en) * | 2015-06-03 | 2017-03-28 | Eileen B. Gallagher | Biological data annotation and visualization |
| US10672505B2 (en) | 2015-06-03 | 2020-06-02 | General Electric Company | Biological data annotation and visualization |
| CN108291216B (zh) | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| CA3009553A1 (en) | 2015-12-23 | 2017-06-29 | Centre National De La Recherche Scientifique | Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof |
| FR3046355A1 (fr) * | 2015-12-30 | 2017-07-07 | Lab Francais Du Fractionnement | Fragments du facteur h pour son utilisation comme agent anti-angiogenique |
| PL3472149T3 (pl) * | 2016-06-21 | 2024-02-12 | Orion Ophthalmology LLC | Heterocykliczne pochodne prolinamidu |
| BR112019012635A2 (pt) * | 2016-12-22 | 2019-11-19 | Daiichi Sankyo Company, Limited | peptídeo mutante spink2, polinucleotídeo, vetor, célula, métodos para produzir um peptídeo mutante spink2, para identificar um fármaco terapêutico ou um fármaco profilático para degeneração macular relacionada à idade, dpara identificar um agente de proteção retinal e para preparar um coelho modelo e dano retinal, conjugado, anticorpo, composição, composição farmacê utica, e, coelho modelo de dano retinal. |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
| EP3697920A4 (en) * | 2017-10-20 | 2022-03-02 | Gemini Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| WO2019215330A1 (en) * | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
| US20210338838A1 (en) * | 2018-07-20 | 2021-11-04 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| JP7222075B2 (ja) * | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
| GB201821089D0 (en) | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| EP4048321A4 (en) * | 2019-10-22 | 2023-11-22 | Applied Genetic Technologies Corporation | ADENO-ASSOCIATED VIRUS (AAV) VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES AND DISORDERS |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| CA3182800A1 (en) | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
| US20230322749A1 (en) | 2020-06-19 | 2023-10-12 | Endogena Therapeutics, Inc. | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium |
| GB202010009D0 (en) * | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| US11541039B2 (en) | 2020-10-08 | 2023-01-03 | Endogena Therapeutics, Inc. | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium |
| GB202107586D0 (en) | 2021-05-27 | 2021-07-14 | Complement Therapeutics Ltd | Inhibitory nucleic acids for Factor H family proteins |
| LU103244B1 (en) | 2024-02-14 | 2025-08-14 | Univ Hamburg Eppendorf Uke | Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5037746A (en) | 1986-12-03 | 1991-08-06 | University Patents, Inc. | RNA ribozyme polymerases, and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| JP2897959B2 (ja) | 1988-05-20 | 1999-05-31 | エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト | 固定化された配列特異的プローブ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0600866T3 (da) | 1990-06-01 | 1998-03-09 | Chiron Corp | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| KR100310939B1 (ko) | 1992-10-01 | 2002-06-20 | 추후제출 | 태그로암호화한복합조합화학라이브러리 |
| DE69333930T8 (de) | 1993-01-22 | 2007-02-22 | The Regents Of The University Of Colorado, Boulder | Lokalisierung von therapeutischen mitteln |
| BR9407947A (pt) | 1993-11-02 | 1996-11-26 | Affymax Tech Nv | Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv |
| US5667969A (en) | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6969601B2 (en) * | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
| US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CN1202246C (zh) | 1998-04-08 | 2005-05-18 | 联邦科学和工业研究组织 | 获得修饰表型的方法和措施 |
| US7312050B2 (en) | 1998-10-29 | 2007-12-25 | University Of Iowa Research Foundation | Nucleic acids encoding interphotoreceptor matrix proteins |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US7108982B1 (en) | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
| DE60031512T2 (de) * | 1999-02-19 | 2007-08-23 | University Of Iowa Research Foundation | Diagnostika und therapeutika für maculare degeneration |
| US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| EP1161686A2 (en) * | 1999-03-05 | 2001-12-12 | University Of Iowa Research Foundation | Diagnostics and therapeutics for drusen associated ocular disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| JP4764590B2 (ja) | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| CN1364780A (zh) * | 2001-01-10 | 2002-08-21 | 上海博德基因开发有限公司 | 一种新的多肽——补体因子h12.32和编码这种多肽的多核苷酸 |
| AU2002307154A1 (en) * | 2001-04-06 | 2002-10-21 | Origene Technologies, Inc | Prostate cancer expression profiles |
| US20060241074A1 (en) | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
| EP1629098B1 (en) | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7553931B2 (en) | 2003-07-03 | 2009-06-30 | Pls-Design Gmbh | Complement depletion using recombinant human C3-derivatives |
| US7300471B2 (en) | 2004-02-27 | 2007-11-27 | L'oreal S.A. | Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes. |
| US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ES2631127T3 (es) * | 2004-06-10 | 2017-08-28 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| JP2008520242A (ja) * | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| US7745389B2 (en) | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| US8101169B2 (en) * | 2005-02-23 | 2012-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Ocular gene therapy using avalanche-mediated transfection |
| US8088587B2 (en) * | 2005-03-04 | 2012-01-03 | Vanderbilt University | Genetic variants increase the risk of age-related macular degeneration |
| US20070037183A1 (en) | 2005-03-07 | 2007-02-15 | Trustees Of Boston University | Diagnostic and therapeutic target for macular degeneration |
| CA2725709A1 (en) * | 2005-06-08 | 2006-12-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N | Susceptibility genes for age-related maculopathy (arm) on chromosome 10q26 |
| US20090220953A1 (en) | 2005-08-24 | 2009-09-03 | C.Y.O'connor Erade Village Foundation | Identification of ancestral haplotypes and uses thereof |
| EP1937706A4 (en) * | 2005-09-09 | 2008-10-22 | Univ Iowa Res Found | ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION |
| US8012683B2 (en) * | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US20080146501A1 (en) | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| EP2479284B1 (en) * | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| EP2054728A2 (en) * | 2006-08-23 | 2009-05-06 | University of Iowa Research Foundation | Biomarkers associated with age-related macular degeneration |
| WO2009059321A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US7952830B2 (en) * | 2009-06-04 | 2011-05-31 | Samsung Electronics Co., Ltd. | Method and apparatus for estimating flying height in a hard disk drive |
-
2006
- 2006-02-14 US US11/354,559 patent/US7745389B2/en active Active
- 2006-02-14 EP EP10185958A patent/EP2377951A1/en not_active Withdrawn
- 2006-02-14 KR KR1020077021213A patent/KR20070112801A/ko not_active Ceased
- 2006-02-14 NZ NZ595305A patent/NZ595305A/xx not_active IP Right Cessation
- 2006-02-14 CA CA2597411A patent/CA2597411C/en not_active Expired - Lifetime
- 2006-02-14 AT AT06735123T patent/ATE526421T1/de not_active IP Right Cessation
- 2006-02-14 KR KR1020137019809A patent/KR20130100207A/ko not_active Ceased
- 2006-02-14 WO PCT/US2006/005313 patent/WO2006088950A2/en not_active Ceased
- 2006-02-14 EP EP10179501.1A patent/EP2302076B1/en not_active Expired - Lifetime
- 2006-02-14 CN CN201410180974.2A patent/CN103920142A/zh active Pending
- 2006-02-14 EP EP10185982.5A patent/EP2357257B1/en not_active Expired - Lifetime
- 2006-02-14 EP EP10179403A patent/EP2357254A1/en not_active Withdrawn
- 2006-02-14 US US11/816,167 patent/US8088579B2/en not_active Expired - Fee Related
- 2006-02-14 AU AU2006214320A patent/AU2006214320C1/en not_active Ceased
- 2006-02-14 EP EP06735123A patent/EP1856287B1/en not_active Expired - Lifetime
- 2006-02-14 JP JP2007555366A patent/JP2008529536A/ja not_active Withdrawn
- 2006-02-14 NZ NZ608860A patent/NZ608860A/en not_active IP Right Cessation
- 2006-02-14 MX MX2007009565A patent/MX2007009565A/es active IP Right Grant
-
2007
- 2007-08-13 IL IL185219A patent/IL185219A/en not_active IP Right Cessation
-
2009
- 2009-06-05 US US12/479,716 patent/US8497350B2/en active Active
- 2009-06-08 US US12/480,588 patent/US20090258822A1/en not_active Abandoned
-
2012
- 2012-03-06 JP JP2012049810A patent/JP5100901B2/ja not_active Expired - Fee Related
- 2012-08-17 JP JP2012180904A patent/JP2012254089A/ja not_active Withdrawn
-
2013
- 2013-03-14 IL IL225203A patent/IL225203A/en active IP Right Grant
- 2013-07-17 US US13/944,845 patent/US20130296255A1/en not_active Abandoned
-
2014
- 2014-06-16 JP JP2014123102A patent/JP2014204729A/ja active Pending
-
2015
- 2015-08-31 US US14/841,456 patent/US20160096871A1/en not_active Abandoned
-
2017
- 2017-07-17 US US15/652,064 patent/US20170369543A1/en not_active Abandoned
-
2019
- 2019-11-06 US US16/676,145 patent/US11168120B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529536A5 (2) | ||
| JP7429318B2 (ja) | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 | |
| US20230235044A1 (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) | |
| JP2020152729A5 (2) | ||
| WO2006088950B1 (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
| US20210196751A1 (en) | Methods of cancer treatment using an atr inhibitor | |
| KR20200044793A (ko) | Aav의 전달을 위한 조성물 및 방법 | |
| JP2007297407A5 (2) | ||
| CA3076982C (en) | Als diagnostic method | |
| CN105209055A (zh) | 用人生长激素类似物治疗小儿生长激素缺乏症 | |
| CN107207577A (zh) | 用于治疗和预防炎症的组合物和方法 | |
| JP2006502702A5 (2) | ||
| CA3236236A1 (en) | Compositions and systems for rna-programmable cell editing and methods of making and using same | |
| JP2009515524A5 (2) | ||
| US10195166B2 (en) | Methods for treating hepatitis C virus infectious disease | |
| US20020037523A1 (en) | IL-6-like polynucleotides, polypeptides, and antibodies | |
| WO2001046475A1 (en) | Trefoil domain-containing polynucleotides, polypeptides, and antibodies | |
| CN101671723A (zh) | 人犬尿氨酸酶基因的单核苷酸多态性组成的单倍型 | |
| CN116253775B (zh) | 靶向抑制slug转录激活作用的多肽及其用途 | |
| CN110157799A (zh) | 用于指导糖尿病个体化用药相关基因多态性检测的引物探针组、试剂盒及方法 | |
| JP7764502B2 (ja) | 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用 | |
| CN100494400C (zh) | 电压调控钠通道7型α亚单位基因与原发性高血压的相关性 | |
| AU2022356375B2 (en) | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists | |
| CN108752452B (zh) | Sars及其突变体的应用 | |
| JP2011101650A5 (2) |